A Study of Pemetrexed in Children With Recurrent Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
OsteosarcomaMedulloblastomaSarcoma, Ewing'sNeuroblastoma (Measurable Disease)Neuroblastoma (MetaiodobenzylguanidinePositive Evaluable)RhabdomyosarcomaEpendymomaNon-brainstem High-grade Glioma
Interventions
DRUG

pemetrexed

1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles

Trial Locations (1)

91066

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arcadia

All Listed Sponsors
collaborator

Children's Oncology Group

NETWORK

lead

Eli Lilly and Company

INDUSTRY

NCT00520936 - A Study of Pemetrexed in Children With Recurrent Cancer | Biotech Hunter | Biotech Hunter